Evidence map›Paper›PMID 25318092›Full record

ArticleClinics (Sao Paulo, Brazil)2014

Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.

Marcelo Passos Teivelis, Nelson Wolosker, Mariana Krutman, Paulo Kauffman, José Ribas Milanez de Campos, Pedro Puech-Leão

Open access · goldAbstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marcelo Passos TeivelisHospital Israelita Albert Einstein, Vascular Surgery, São Paulo, SP, Brazil.
Nelson WoloskerHospital Israelita Albert Einstein, Vascular Surgery, São Paulo, SP, Brazil.
Mariana KrutmanHospital Israelita Albert Einstein, Vascular Surgery, São Paulo, SP, Brazil.
Paulo KauffmanHospital Israelita Albert Einstein, Vascular Surgery, São Paulo, SP, Brazil.
José Ribas Milanez de CamposHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP), Thoracic Surgery Division, São Paulo, SP, Brazil.
Pedro Puech-LeãoDepartment of Surgery, Vascular and Endovascular Surgery Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP), São Paulo, SP, Brazil.
Hospital Israelita Albert Einstein · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPrimary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and groin).

methodsThis retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to measure their improvement at each site of excessive sweating after six weeks and at the last consult.

resultsThe median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth. Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one: palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main sites of sweating.

conclusionAfter six weeks, more than 80% of the patients presented with improvements in their overall quality of life and at the most important site of sweating. Side effects were common (80% reported at least one side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects.

Indexed as

Quality of LifeAdolescentAdultAgedFemaleFollow-Up StudiesHumansHyperhidrosisMaleMandelic AcidsMiddle AgedMuscarinic AntagonistsRetrospective StudiesTime FactorsTreatment OutcomeXerostomiaMandelic AcidsMuscarinic Antagonistsoxybutynin

Identifiers

PMID25318092
PMCPMC4192402
OpenAlexW1995845881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.